Abiomed Announces First Impella RP Patient Enrolled in Recover Right Study

Mon Apr 1, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.


DANVERS, Mass., April 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc.
 (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the
enrollment of the first patient in RECOVER RIGHT, an Investigational Device Exemption (IDE) study
of Impella RP (Right Peripheral).

The Impella RP is a percutaneous heart pump that is implanted through a single access site in the
patient's leg and deployed through the venous system, across the right side of the heart without
requiring a surgical procedure.

The RECOVER RIGHT clinical study, which received FDA IDE approval to begin in November 2012, will
enroll 30 patients that present with signs of right side heart failure, require hemodynamic
support, and are being treated in the catheterization lab or cardiac surgery suite. 

The following two patient cohorts will be examined in the RECOVER RIGHT study:

1)  Patients that develop right side heart failure within 48 hours post-left ventricular assist
device (LVAD) implantation;

2)  Patients that develop right side heart failure subsequent to post-cardiotomy shock within 48
hours post surgery or post myocardial infarction.

The first enrollment in the RECOVER RIGHT study was a patient who developed right ventricular
dysfunction after receiving an implantable LVAD. The Impella RP was implanted at Einstein Medical
Center Philadelphia under the leadership of Mark Anderson, M.D., FACS, Chair of the Division of
Cardiothoracic Surgery at Einstein. The Impella RP implant was performed by Christian Witzke,
M.D., Director of the Structural Heart Disease Program and Parul Patel, MD., Director of the
Cardiac Catheterization Laboratory at Einstein Medical Center Philadelphia. 

"This is another example of how Einstein Healthcare Network is committed to providing the best
possible outcomes for patients by conducting clinical trials to assess the safety and probable
benefit of innovative technologies such as the Impella RP pump," added Dr. Anderson, who is
co-principal investigator of the RECOVER RIGHT study with William O'Neill, M.D., medical director
of the Center for Structural Heart Disease at Henry Ford Hospital.

"The Impella RP gave this patient a level of hemodynamic support that allowed our heart failure
team to treat the patient's right-sided heart failure quickly in a minimally invasively manner,"
said Dr. Witzke.

The Impella RP is currently the subject of an investigational device exemption (IDE) clinical
study and is not currently approved for sale in the United States.


Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that
provide circulatory support. Our products are designed to enable the heart to rest by improving
blood flow and/or performing the pumping of the heart. For additional information please visit:


This release contains forward-looking statements, including statements regarding development of
Abiomed's existing and new products, the Company's progress toward commercial growth, and future
opportunities and expected regulatory approvals. The Company's actual results may differ
materially from those anticipated in these forward-looking statements based upon a number of
factors, including uncertainties associated with development, testing and related regulatory
approvals, including the potential for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition, technological change,
government regulation, litigation matters, future capital needs and uncertainty of additional
financing, and other risks and challenges detailed in the Company's filings with the Securities
and Exchange Commission, including the most recently filed Annual Report on Form 10-K and
quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this release. The Company
undertakes no obligation to publicly release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances that occur after the date of this
release or to reflect the occurrence of unanticipated events.

CONTACT: Susie Lisa, CFA
         Senior Director, Investor Relations and Corporate Development
         Aimee Genzler
         Corporate Communications Manager

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.